(Q46684439)

24 December 2017

title

Cardiac manifestations of Anderson-Fabry disease in children and adolescents (English)

1 reference

24 December 2017

1 reference

1 reference

5

Eugen Mengel

1 reference

24 December 2017

Christoph Kampmann

1

1 reference

24 December 2017

Christiane M Wiethoff

2

1 reference

24 December 2017

Catharina Whybra

3

1 reference

24 December 2017

Frank A Baehner

4

1 reference

24 December 2017

Michael Beck

6

1 reference

24 December 2017

language of work or name

English

0 references

publication date

1 April 2008

1 reference

24 December 2017

published in

Acta Paediatrica

1 reference

24 December 2017

volume

97

1 reference

24 December 2017

issue

4

1 reference

24 December 2017

page(s)

463-469

1 reference

24 December 2017

Clinical features of and recent advances in therapy for Fabry disease

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1651-2227.2008.00700.X

21 January 2018

Pediatric Fabry disease

1 reference

https://api.crossref.org/works/10.1111%2FJ.1651-2227.2008.00700.X

The early clinical phenotype of Fabry disease: a study on 35 European children and adolescents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1651-2227.2008.00700.X

Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1651-2227.2008.00700.X

Quality of life of patients with Fabry disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1651-2227.2008.00700.X

Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1651-2227.2008.00700.X

The heart in Fabry's disease. A histochemical and electron microscopic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1651-2227.2008.00700.X

The heart in Anderson-Fabry disease and other lysosomal storage disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1651-2227.2008.00700.X

Cerebrovascular brainstem diseases with isolated cranial nerve palsies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1651-2227.2008.00700.X

Cardiac manifestations of Anderson-Fabry disease in heterozygous females

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1651-2227.2008.00700.X

Normal values of M mode echocardiographic measurements of more than 2000 healthy infants and children in central Europe

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1651-2227.2008.00700.X

Diabetic autonomic neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1651-2227.2008.00700.X

Impact of reduced heart rate variability on risk for cardiac events. The Framingham Heart Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1651-2227.2008.00700.X

Heart rate variability in healthy children and adolescents is partially related to age and gender.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1651-2227.2008.00700.X

Circadian rhythm of heart rate and heart rate variability

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1651-2227.2008.00700.X

The ability of several short-term measures of RR variability to predict mortality after myocardial infarction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1651-2227.2008.00700.X

Enzyme-replacement therapy with agalsidase alfa in children with Fabry disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1651-2227.2008.00700.X

Enhanced endothelium-dependent vasodilation in Fabry disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1651-2227.2008.00700.X

Regional cerebral hyperperfusion and nitric oxide pathway dysregulation in Fabry disease: reversal by enzyme replacement therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1651-2227.2008.00700.X

Enzyme replacement therapy in Fabry disease: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1651-2227.2008.00700.X

Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1651-2227.2008.00700.X

Long-term safety and efficacy of enzyme replacement therapy for Fabry disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1651-2227.2008.00700.X

Effects of enzyme replacement therapy on pain and health related quality of life in patients with Fabry disease: data from FOS (Fabry Outcome Survey).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1651-2227.2008.00700.X

Enzyme replacement therapy in Fabry disease patients undergoing dialysis: effects on quality of life and organ involvement.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1651-2227.2008.00700.X

10.1111/J.1651-2227.2008.00700.X

21 January 2018

Identifiers

DOI

1 reference

24 December 2017

PubMed ID

18363956

1 reference

24 December 2017